EPISODE 24: WHAT TO KNOW ABOUT GRADE 3 WELL-DIFFERENTIATED NETS

Download the transcript here:

ABOUT THIS EPISODE

What are grade 3 NETs and how is it different from grade 3 NEC and other types of NETs? Dr. Mohamad (Bassam) Sonbol from Mayo Clinic in Phoenix, Arizona, enlightens us on this fairly new entity, including treatment options, treatment sequencing and clinical trials.

MEET DR. MOHAMAD BASSAM SONBOL

Mohamad Bassam Sonbol, M.D., is an Oncologist, with special interest in neuroendocrine tumors and gastrointestinal malignancies. In addition to his clinical activities, Dr. Sonbol is active in research that focuses on investigating novel treatments including targeted therapies, immunotherapy, and other agents that could potentially help patients with neuroendocrine and gastrointestinal cancers. Dr. Sonbol focuses on the holistic treatment for cancer patients taking into consideration their medical and social aspects that have been affected by their cancer diagnosis.

TOP 10 QUESTIONS

1. What are grade 3 NETs? Where are they located? How is grade 3 NETs different from other types of NETs? In particular, how is it different from grade 3 NEC? Can NET change into NEC?

2. How are grade 3 NETs found? How does one know it is grade 3?

3. What types of labs, scans, or testing is done to determine if someone has a grade 3 NET?

4. Can a grade 3 NET be surgically removed? How would you decide if, when, and how?

5. How are grade 3 NETs treated medically (or nonsurgically)? How are treatments sequenced?

6. How are the treatments different from other NETs?

7. How are grade 3 NETs monitored? What types of bloodwork or tests should be done and how often should they be done? What is the best type of scan for grade 3 NETs?

8. Can the tumors change in grade, Ki-67, and differentiation? What is the likelihood of NET changing to NEC and is there anything that can predict this or prevent this from happening?

9. What are clinical trials we should be aware of or exciting new treatments in the pipeline for grade 3 NETs?

10. What words of hope would you like to leave the NET community with?

RESOURCES 

Click here for more resources for high-grade >>

CLINICAL TRIALS MENTIONED IN THIS EPISODE

• CABINET: Cabozantinib in Advanced pNET and Carcinoid Tumors

• COMPOSE: PRRT with Lu-177 EDOTREOTIDE versus “Standard of Care” in Well-Differentiated Aggressive G2 & G3 GEP-NETS

• ComPareNET: Lu-177 DOTATATE vs CAPTEM in Advanced pNETs

WATCH

NET Patient Kimberly shares her NET journey, including Dr. Sonbol's impact (mentioned in this podcast, but not a G3 NET patient)

NET Patient Denny shares his story of living with a G3 NET

READ

• Management of Well-Differentiated High-Grade (G3) Neuroendocrine Tumors

• Treatment Outcomes of Well-Differentiated High-Grade Neuroendocrine Tumors

• Expert Consensus Practice Recommendations of the North American Neuroendocrine Tumor Society for the management of high grade gastroenteropancreatic and gynecologic neuroendocrine neoplasms in: Endocrine-Related Cancer Volume 30 Issue 8 (2023)

• Is There a Role for Surgical Resection of Grade 3 Neuroendocrine Neoplasms?  

DISCLAIMER

LACNETS Podcasts are created for educational purposes only and do not substitute for medical advice. The views shared in this Podcast are the personal opinions of the experts and do not necessarily reflect the views of LACNETS. Please contact your medical team with questions or concerns about your individual care or treatment.

THANK YOU TO OUR SPONSORS